Takeda is to transfer all of its 49% outstanding shares in its affiliate Teva Takeda Pharma Ltd, to Teva Pharmaceutical Industries Ltd (Teva), in response to Teva’s plans to transfer 100% of Teva Takeda Pharma to JKI Co Ltd.

Teva expects the divestiture to be completed by April 2025, subject to standard closing conditions, including obtaining required regulatory approvals. Upon completion of this share transfer, Teva Takeda Pharma will no longer be an affiliate of Takeda. Takeda will continue to distribute the medicines belonging to Teva Takeda Pharma and its 100% subsidiary Takeda Teva Yakuhin for which it is currently responsible. Teva Takeda Pharma is a joint venture established in 2016 by Takeda and Teva, focusing primarily on the business of generic and off-patent medicines.